An Australian vote for pharma: biosimilars
This article was originally published in Scrip
Executive Summary
Somatropin is the only biosimilar product on the Australian market. (In Europe, by contrast, 17 biosimilars of five different molecules have been approved since 2006.) This synthetic growth hormone recorded sales of $45,000 in 2009, although the market is still very much dominated by the original branded product: Pfizer's Genotropin and Genotropin MiniQuick. Three years after the first biosimilar was launched, the biosimilar somatropin market accounted for 0.4% of total somatropin sales.